EUVIMEDEUVIMED entdecken
Crossref

Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients

Shinya Takada, Hideki Maeda, Kengo Umehara, Sayuri Kuwahara, Mitsugu Yamamoto, Nobumoto Tomioka, Kenichi Watanabe, Kozo Mino

Biological and Pharmaceutical Bulletin · 2023

DOI: 10.1248/bpb.b23-00187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Shinya Takada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Neutropenia, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapy for patients of metastatic breast cancer based on palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has been approved in Japan. However, the risk factors for palbociclib-induced severe neutropenia in Japanese patients are rarely reported. Hence, the present study is aimed to identify the risk factors for adverse events requiring palbociclib dose reduction or discontinuation, and to identify the factors necessary to identify a more stable strategy for treatment continuation. This retrospective cohort analysis included patients with advanced breast cancer treated with 125 mg/d palbociclib. We demonstrated that severe neutropenia required significant dose reduction or therapy cessation. Most (77%) of the patients had severe neutropenia within the three courses. Risk factors for grade 3 or higher included low neutrophil counts ( 9) [OR = 1.64, 95% CI (1.09-2.48), p = 0.018]. Thus, low baseline neutrophil counts and high values for Age-adjusted Charlson comorbidity index are prospective predictive markers for palbociclib-induced severe neutropenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsNeutropeniaAntineoplastic AgentsFemaleHumansEast Asian PeopleProspective StudiesErb-b2 Receptor Tyrosine KinasesRetrospective StudiesPiperazinesPyridines

Stichwörter der Autor:innen

age-adjusted Charlson comorbidity indexbreast cancercyclin-dependent kinase 4/6 inhibitorpalbociclibsevere neutropenia

Substanzen

Erb-b2 Receptor Tyrosine KinasesAntineoplastic AgentspalbociclibPiperazinesPyridines

Autor:innen und Institutionen

  • Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center.
  • Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center.

Zitieren

APA

Takada, S., Maeda, H., Umehara, K., Kuwahara, S., Yamamoto, M., Tomioka, N., Watanabe, K., & Mino, K. (2023). Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b23-00187

Vancouver

Takada S, Maeda H, Umehara K, Kuwahara S, Yamamoto M, Tomioka N, et al. Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b23-00187

BibTeX
@article{Takada2023,
  author = {Takada, Shinya and Maeda, Hideki and Umehara, Kengo and Kuwahara, Sayuri and Yamamoto, Mitsugu and Tomioka, Nobumoto and Watanabe, Kenichi and Mino, Kozo},
  title = {Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2023},
  doi = {10.1248/bpb.b23-00187}
}
Kostenlos starten →